Robert D. Toto

33.1k total citations · 12 hit papers
250 papers, 21.2k citations indexed

About

Robert D. Toto is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Robert D. Toto has authored 250 papers receiving a total of 21.2k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Nephrology, 96 papers in Cardiology and Cardiovascular Medicine and 84 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Robert D. Toto's work include Blood Pressure and Hypertension Studies (79 papers), Chronic Kidney Disease and Diabetes (61 papers) and Diabetes Treatment and Management (55 papers). Robert D. Toto is often cited by papers focused on Blood Pressure and Hypertension Studies (79 papers), Chronic Kidney Disease and Diabetes (61 papers) and Diabetes Treatment and Management (55 papers). Robert D. Toto collaborates with scholars based in United States, United Kingdom and Netherlands. Robert D. Toto's co-authors include Andrew S. Levey, George L. Bakris, Dick de Zeeuw, John J.V. McMurray, Tom Greene, Domenic Sica, William B. White, Robert M. Carey, David A. Calhoun and Timothy F. Murphy and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Robert D. Toto

243 papers receiving 20.5k citations

Hit Papers

Resistant Hypertension: Diagnosis, Evaluation... 1992 2026 2003 2014 2008 2009 2002 2000 2008 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Resistant Hypertension: Diagnosis, Evaluation, and Treatment
    2008 1.7k citations Robert D. Toto, Domenic Sica et al. Circulation profile →
  2. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
    2009 1.4k citations Mark E. Cooper, Dick de Zeeuw et al. profile →
  3. Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
    2002 1.3k citations Garabed Eknoyan, Gerald J. Beck et al. profile →
  4. Preserving renal function in adults with hypertension and diabetes: A consensus approach
    2000 1.1k citations Robert D. Toto et al. American Journal of Kidney Diseases profile →
  5. Resistant Hypertension: Diagnosis, Evaluation, and Treatment
    2008 1.0k citations Robert D. Toto, Domenic Sica et al. profile →
  6. Sympathetic Overactivity in Patients with Chronic Renal Failure
    1992 854 citations Robert D. Toto et al. profile →
  7. Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
    2013 784 citations Dick de Zeeuw, Hiddo J.L. Heerspink et al. profile →
  8. Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis
    2003 775 citations Tazeen H. Jafar, Dick de Zeeuw et al. Annals of Internal Medicine profile →
  9. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
    2018 756 citations Julio Rosenstock, Vlado Perkovic et al. profile →
  10. Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
    2011 707 citations Robert D. Toto et al. profile →
  11. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
    2020 355 citations David C. Wheeler, Bergur V. Stefánsson et al. profile →
  12. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
    2021 237 citations David C. Wheeler, Robert D. Toto et al. Kidney International profile →

Peers

Robert D. Toto
Julia B. Lewis United States
Paul E. de Jong Netherlands
Mark J. Sarnak United States
David C. Wheeler United Kingdom
Chi‐yuan Hsu United States
Lawrence G. Hunsicker United States
Kunihiro Matsushita United States
Ron T. Gansevoort Netherlands
Johannes F.E. Mann Germany
Alejandro Castro Spain
Julia B. Lewis United States
Robert D. Toto
Citations per year, relative to Robert D. Toto Robert D. Toto (= 1×) peers Julia B. Lewis

Countries citing papers authored by Robert D. Toto

Since Specialization
Citations

This map shows the geographic impact of Robert D. Toto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert D. Toto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert D. Toto more than expected).

Fields of papers citing papers by Robert D. Toto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert D. Toto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert D. Toto. The network helps show where Robert D. Toto may publish in the future.

Co-authorship network of co-authors of Robert D. Toto

This figure shows the co-authorship network connecting the top 25 collaborators of Robert D. Toto. A scholar is included among the top collaborators of Robert D. Toto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert D. Toto. Robert D. Toto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bui, Lan N., Joshua Lambert, Victor Ortiz-Soriano, et al.. (2025). Change in platelet and leukocyte counts and hospital mortality in adults with acute kidney injury receiving continuous renal replacement therapy. Scientific Reports. 15(1). 33553–33553.
2.
Bakker, W, Hiddo J.L. Heerspink, Niels Jongs, et al.. (2025). Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD. Journal of the American Society of Nephrology. 37(1). 101–109. 1 indexed citations
3.
Ku, Elaine, Lesley A. Inker, Hocine Tighiouart, et al.. (2024). Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease. Annals of Internal Medicine. 177(7). 953–963. 14 indexed citations
4.
Veličković, Dušan, John P. Shapiro, Samir V. Parikh, et al.. (2024). Protein N-Glycans in Healthy and Sclerotic Glomeruli in Diabetic Kidney Disease. Journal of the American Society of Nephrology. 35(9). 1198–1207. 7 indexed citations
5.
Ku, Elaine, Hocine Tighiouart, Charles E. McCulloch, et al.. (2024). Association between Acute Declines in eGFR during Renin-Angiotensin System Inhibition and Risk of Adverse Outcomes. Journal of the American Society of Nephrology. 35(10). 1402–1411. 6 indexed citations
6.
Fletcher, Robert A., Niels Jongs, Glenn M. Chertow, et al.. (2023). Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials. Journal of the American Society of Nephrology. 34(12). 1965–1975. 14 indexed citations
7.
Persson, Frederik, Niels Jongs, Gozewijn D. Laverman, et al.. (2023). Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. Diabetes Care. 46(3). 602–607. 9 indexed citations
8.
Ferguson, Joanne, Raina Ramnath, Karen L. Onions, et al.. (2023). Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx. JCI Insight. 8(5). 19 indexed citations
9.
Berry, Jarett D., Haiying Chen, Vijay Nambi, et al.. (2022). Effect of Intensive Blood Pressure Control on Troponin and Natriuretic Peptide Levels: Findings From SPRINT. Circulation. 147(4). 310–323. 13 indexed citations
10.
Vart, Priya, David Z.I. Cherney, Glenn M. Chertow, et al.. (2022). Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia. 65(7). 1085–1097. 35 indexed citations
11.
Chertow, Glenn M., Priya Vart, Niels Jongs, et al.. (2021). Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. UCL Discovery (University College London). 80 indexed citations
12.
Perkovic, Vlado, Robert D. Toto, Mark E. Cooper, et al.. (2020). Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care. 43(8). 1803–1812. 42 indexed citations
13.
Toto, Robert D., et al.. (2020). A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. Journal of the American Society of Nephrology. 32(2). 469–478. 1 indexed citations
14.
McGuire, Darren K., John H. Alexander, Odd Erik Johansen, et al.. (2019). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 139(3). 351–361. 112 indexed citations
15.
Wang, Xuelei, Julia B. Lewis, Lawrence J. Appel, et al.. (2006). Validation of Creatinine-Based Estimates of GFR When Evaluating Risk Factors in Longitudinal Studies of Kidney Disease. Journal of the American Society of Nephrology. 17(10). 2900–2909. 58 indexed citations
16.
Reddan, Donal, Lynda A. Szczech, Vic Hasselblad, et al.. (2005). Intradialytic Blood Volume Monitoring in Ambulatory Hemodialysis Patients. Journal of the American Society of Nephrology. 16(7). 2162–2169. 151 indexed citations
17.
Greene, Tom, John T. Daugirdas, Thomas A. Depner, et al.. (2005). Association of Achieved Dialysis Dose with Mortality in the Hemodialysis Study. Journal of the American Society of Nephrology. 16(11). 3371–3380. 56 indexed citations
18.
Zhang, Zhongxin, et al.. (2004). Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney International. 66(3). 1131–1138. 172 indexed citations
19.
20.
Hootkins, Robert, et al.. (1993). Improved kinetic modeling to prevent dialysis complications: Variability and stability of urea mass transfer coefficient. Blood Purification. 11(1). 80–81. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julia B. Lewis Breakdown of academic impact, for papers by Paul E. de Jong Breakdown of academic impact, for papers by Mark J. Sarnak Breakdown of academic impact, for papers by David C. Wheeler Breakdown of academic impact, for papers by Chi‐yuan Hsu Breakdown of academic impact, for papers by Lawrence G. Hunsicker Breakdown of academic impact, for papers by Kunihiro Matsushita Breakdown of academic impact, for papers by Ron T. Gansevoort Breakdown of academic impact, for papers by Johannes F.E. Mann Breakdown of academic impact, for papers by Alejandro Castro
Rankless by CCL
2026